Free Version

Upgrade subject to access all content


Signaling Cascade Downstream of Dopamine Receptor Activation


D1 and D5 dopamine receptors are coupled to the $G_s$ subtype of G-proteins. Pharmacological inhibition of dopamine receptors D1/D5 in the medial prefrontal cortex (mPFC) causes attention deficit and hyperactivity.

Changes in gene expression are necessary for the appearance of attention deficit and hyperactivity symptoms upon inhibition of D1/D5 receptors. These changes in gene expression are caused by transcription factor cAMP response element binding protein (CREB). Rp-cAMPS is a cell permeable drug that inhibits PKA.

What effects of Rp-cAMPS microinjection into mPFC do you expect to see?


Increased phosphorylation of CREB and hypoactivity.


Changes in gene expression consistent with activation of CREB and hypoactivity.


Reduced phosphorylation of CREB, attention deficit and hyperactivity.


No change in CREB phosphorylation, attention deficit and hyperactivity.